Results 31 to 40 of about 7,760 (160)

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Azaadamantane Benzamide 5-HT4 Agonists: Gastrointestinal Prokinetic SC-54750 [PDF]

, 2004
Azaadamantanone 1 was converted to a series of aminoazaadamantane benzamides 9a–d, which were profiled for serotonin receptor activity. Aminomethylazaadamantane SC-54750 is a potent 5-HT4 agonist and 5-HT3 antagonist with in vivo efficacy in ...
Becker, Daniel, Flynn, Daniel L., Gullikson, Gary, Shone, Robert L.   +3 more
core   +1 more source

Iloperidone treatment mitigates the Juvenile Huntington's Disease phenotype possibly via Sigma‐1 Receptor Modulation

The FEBS Journal, EarlyView.
We investigated the potential of iloperidone as an activator of Sigma‐1 receptor (S1R) neuroprotective function in juvenile Huntington's disease (jHD). We tested iloperidone on cortical neurons differentiated from patient‐derived iPSCs, demonstrating that it acts as a S1R agonist, decreasing apoptosis, huntingtin aggregation, and oxidative stress ...
Ersilia Fornetti, Gaia Galluzzi, Mario Frezzini, Cécile Exertier, Vittorio Brufani, Gianni Colotti, Giancarlo Ruocco, Jessica Rosati, Angelo Luigi Vescovi, Daniele Narzi, Ilaria Genovese, Andrea Ilari   +11 more
wiley   +1 more source

Drugs Affecting 5-HT Systems [PDF]

, 2013
Seminar transcriptIt was in the very early hours of a February morning in 1977 that I first looked down the microscope and saw yellow fluorescence, characteristic of 5-hydroxytryptamine (5-HT) in frozen sections of Octopus brain. After struggling for two
Overy, C, Tansey, EM
core  

A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression [PDF]

, 2015
Major depressive disorder (MDD) is primarily conceptualized as a mood disorder but cognitive dysfunction is also prevalent, and may limit the daily function of MDD patients.
Alan L. Pehrson, Connie Sanchez, Elena Dale, Jessica A. Waller, Maria Gulinello, Yan Li   +5 more
core   +2 more sources

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source

Pharmacologic MRI Brain Imaging Studies of Serotonin 5‐HT1 Receptor Agonists in Awake Mice

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Serotonin (5‐hydroxytryptamine, 5‐HT) type‐1 G protein‐coupled receptors are expressed throughout the central nervous system. 5‐HT1AR activation is the putative mechanism of approved drugs for generalized anxiety disorder and major depressive disorder and is being studied in the treatment of autism and neurological disorders.
Brittany M. Brems, Erin E. Sullivan, Ryan P. McGlynn, Praveen Kulkarni, Craig F. Ferris, Raymond G. Booth   +5 more
wiley   +1 more source

Targeting the noradrenergic‐metabolic axis: A new strategy for sugar‐induced depression subtypes

British Journal of Pharmacology, Volume 183, Issue 9, Page 2099-2122, May 2026.
Abstract Background and Purpose Lifestyle is closely related to major depressive disorder (MDD). Given the growing focus on the impact of diet on mental health, this study examined how dietary habits affect the pathophysiology of MDD. Experimental Approach Health check‐up data were analysed. Mice received sucrose under chronic unpredictable mild stress
Takatoshi Sakata, Kazuo Kunisawa, Masaya Hasegawa, Yumiko Seto, Aoi Ogawa, Hitomi Kurahashi, Yasuko Yamamoto, Masao Takemura, Hidetoshi Matunami, Tomoya Sugai, Noriki Kutsumura, Kuniaki Saito, Toshitaka Nabeshima, Akihiro Mouri   +13 more
wiley   +1 more source

Triptans and CGRP blockade - impact on the cranial vasculature [PDF]

, 2017
The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide ...
Alejandro Labastida-Ramírez, Anne Luise Vollesen, Christian Lampl, Francesca Cortese, Francesca Marchese, Lanfranco Pellesi, Messoud Ashina, Michele Romoli, On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS), Silvia Benemei   +9 more
core   +3 more sources